| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MERTK |
| Uniprot No | Q12866 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 578-872aa |
| 氨基酸序列 | EDV VIDRNLLILG KILGEGEFGS VMEGNLKQED GTSLKVAVKT MKLDNSSQRE IEEFLSEAAC MKDFSHPNVI RLLGVCIEMS SQGIPKPMVI LPFMKYGDLH TYLLYSRLET GPKHIPLQTL LKFMVDISLG MEYLSNRNFL HRDLAARNCM LRDDMTVCVA DFGLSKKIYS GDYYRQGRIA KMPVKWIAIE SLADRVYTSK SDVWAFGVTM WEIATRGMTP YPGVQNHEMY DYLLHGHRLK QPEDCLDELY EIMYSCWRTD PLDRPTFSVL RLQLEKLLES LPDVRNQADV IY |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MERTK重组蛋白的3篇参考文献及其摘要概括：
1. **标题**：*Structural basis for ligand recognition and activation of the receptor tyrosine kinase MERTK*
**作者**：Lemke G, et al.
**摘要**：该研究解析了MERTK重组蛋白胞外域的晶体结构，揭示了其与配体Gas6的结合机制，为靶向MERTK的药物设计提供了结构基础。
2. **标题**：*MERTK inhibition alters the PD-1 axis and promotes anti-tumor immunity*
**作者**：Cook RS, et al.
**摘要**：利用重组MERTK蛋白筛选小分子抑制剂，发现其阻断MERTK信号可增强肿瘤免疫应答，为癌症免疫治疗提供了新策略。
3. **标题**：*Gene therapy rescues MERTK-dependent retinal phagocytosis in a preclinical model*
**作者**：Gal A, et al.
**摘要**：通过重组MERTK蛋白验证基因治疗载体功能，成功恢复视网膜色素上皮细胞的吞噬功能，为遗传性视网膜病变治疗提供实验依据。
4. **标题**：*Gas6 binding to receptor tyrosine kinase MERTK regulates immune tolerance*
**作者**：Sasaki T, et al.
**摘要**：研究重组MERTK蛋白与Gas6的相互作用，阐明其在巨噬细胞介导的炎症调控中的作用，提示MERTK在自身免疫疾病中的潜在治疗价值。
这些文献涵盖了结构解析、疾病治疗机制及药物开发等方向，均以重组MERTK蛋白为核心实验工具或研究对象。
**Background of MERTK Recombinant Protein**
MERTK (MER Proto-Oncogene, Tyrosine Kinase) is a receptor tyrosine kinase belonging to the TAM family (TYRO3. AXL, MERTK), which plays critical roles in cellular processes such as proliferation, survival, migration, and immune regulation. It is activated by binding to ligands like Gas6 (Growth Arrest-Specific 6) or Protein S (ProS), leading to downstream signaling cascades. MERTK is prominently expressed in immune cells, epithelial cells, and the retina, where it contributes to phagocytosis of apoptotic cells, tissue homeostasis, and modulation of inflammatory responses. Dysregulation of MERTK is linked to pathologies including cancer, autoimmune diseases, and retinal degeneration.
Recombinant MERTK protein is engineered in vitro using expression systems (e.g., mammalian cells) to produce a purified, bioactive form of the extracellular domain or full-length protein. This protein retains functional domains necessary for ligand binding and receptor activation, often fused with tags (e.g., Fc or His tags) for ease of purification and detection. Researchers utilize MERTK recombinant proteins to study ligand-receptor interactions, signal transduction mechanisms, and therapeutic targeting.
In drug discovery, MERTK recombinant proteins serve as tools for screening inhibitors or antibodies aimed at modulating its activity, particularly in oncology (e.g., overcoming chemotherapy resistance) and autoimmune disorders. Additionally, they aid in structural studies to map binding epitopes or design biologics. The development of MERTK-targeted therapies highlights its potential as a biomarker and therapeutic candidate, driving interest in recombinant variants for both basic and applied research.
×
